ACADIA Pharmaceuticals Inc. vs Synchrony Financial — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.52 (market cap $5.07B), while Synchrony Financial trades at $78.37 (market cap $25.53B). The key difference: Synchrony Financial is far larger — about 5× ACADIA Pharmaceuticals Inc.'s market cap, and Synchrony Financial pays a 1.73% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | SYF | |
|---|---|---|
Market Cap | $5.07B | $25.53B |
Sector | Health | Financials |
52-Week High | $29.41 | $88.47 |
52-Week Low | $20.06 | $63.78 |
Enterprise Value | $4.19B | — |
Dividend Yield | — | 1.73% |
Trailing returns across standard periods
Latest headlines on both assets
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →